CLAIM CARD
This synthesis maps 34 included sources on Biomarker Effects across 8 outcome classes and 222 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.
Evidence grade: exploratory
Contradiction status: none
Publication: 28e97af9-673c-40ac-80cf-287f334b5af8
Provenance: Derivation Web chain
Citation Support
source_1Lyra 2026source_2Ramos-Hernandez 2026source_3Davidson 2025source_4Alonso 2026source_5Skerrett 2026